AnaMar Medical AB

Development and research of diagnostic, prognostic and therapeutic products based on connective tissue biology targeting joint diseases

Prof. Dick Heinegard and Prof. Tore Saxne of Lund University founded the company AnaMar Medical AB in 1998. The company collaborates with Lund University, especially with the Department of Rheumatology, in development and research.

Owe Gårlin, CEO
Jan Hed, Scientific advisor
Gunilla Ekström, VP, R&D
Pär Lindgren, VP, Sales & Marketing

Staffan Encrantz, Chairman
Ingemar Lagerlöf, Chairman
Ingemar Aldén
Torbjörn Björstrand
Thomas Hedner

Kungsportsavenyn 22
SE-411 36 Göteborg
Sweden
Phone: +46-31-732-4140
Fax: +46-31-732-4149

AnaMar Medical focuses on the sector of connective tissue repair by developing molecular markers for the diagnosis, prognosis and therapy of joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA).

Their products target the detection of cartilage destructions as an indication of RA and OA and its phase of progression by blood tests. A physical response of destructive cartilage and damaged joint is the diffusion of molecule fragments into the cartilage surrounding fluid and into the bloodstream. AnaMar’s technology is based on a Cartilage Oligomeric Matrix Protein (COMP) that belongs to this group of monitoring molecule fragments.

AnaMar’s first product, Human COMP ELISA 14-1006-71, is a method for the detection of COMP in the patient’s serum.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.